Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : K-679
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
K-679 Unimicelle Drug Shows Efficacy in EGFR-Positive Solid Tumors
Details : K-679 is a novel, ultra-high-DAR antibody drug-loaded unimicelle conjugate (ADUC) enabling more effective treatment in EGFR-expressing solid tumors compared to general ADCs.
Product Name : K-679
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
April 21, 2025
Lead Product(s) : K-679
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable